Full text is available at the source.
Effect of chiglitazar and sitagliptin on glucose variations, insulin resistance and inflammatory-related biomarkers in untreated patients with type 2 diabetes
Chiglitazar and sitagliptin's effects on blood sugar swings, insulin resistance, and inflammation markers in untreated type 2 diabetes
AI simplified
Abstract
After 24 weeks, chiglitazar therapy significantly improved insulin resistance and inflammatory parameters compared to sitagliptin in patients with type 2 diabetes mellitus.
- Both chiglitazar and sitagliptin resulted in similar reductions in hemoglobin A1c levels.
- Chiglitazar and sitagliptin reduced the 24-hour mean blood glucose, standard deviation, and mean amplitude of glycemic excursion.
- Chiglitazar therapy increased the time in range for blood glucose levels.
- Significant improvements in insulin resistance and insulin secretion were observed with chiglitazar compared to sitagliptin.
- Chiglitazar administration led to lower levels of inflammatory markers such as interleukin-6 and prostaglandin F2α.
AI simplified